newsfilter
← Latest News
PR Newswire·

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

  • IDEAYA Biosciences' Board of Directors elected Yujiro S. Hata as Chairman.
  • Hata currently serves as President, Chief Executive Officer, & Board member.
  • Terry Rosen, Ph.D., has been appointed as Lead Independent Director.
  • Rosen praised Hata's leadership in evolving the company from a start-up to a precision medicine oncology firm with commercial launch preparations underway.
  • Hata expressed gratitude for the opportunity to advance the company's cancer research & deliver breakthrough therapies.
  • IDEAYA focuses on discovering & commercializing targeted therapies for solid tumors using small-molecule drug discovery, structural biology, & bioinformatics.
  • The company's pipeline includes product candidates focused on synthetic lethality & antibody-drug conjugates (ADCs).
  • The press release includes standard forward-looking statements regarding development, commercialization, & regulatory risks.
  • Joshua Bleharski, Ph.D., Chief Financial Officer, is listed as the Investor & Media contact.